NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 184 filers reported holding NEVRO CORP in Q3 2022. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $372,632 | -42.7% | 14,659 | -18.5% | 0.05% | -42.0% |
| Q1 2023 | $650,339 | -70.5% | 17,990 | -67.7% | 0.09% | -75.4% |
| Q4 2022 | $2,206,314 | +43.5% | 55,715 | +68.9% | 0.36% | +53.2% |
| Q3 2022 | $1,537,000 | -7.4% | 32,987 | -12.8% | 0.23% | +59.6% |
| Q2 2022 | $1,659,000 | +538.1% | 37,842 | +953.8% | 0.15% | +563.6% |
| Q1 2022 | $260,000 | -76.4% | 3,591 | -43.7% | 0.02% | -70.7% |
| Q4 2020 | $1,104,000 | -70.9% | 6,375 | -89.5% | 0.08% | -65.1% |
| Q1 2019 | $3,796,000 | +12.0% | 60,729 | -30.3% | 0.22% | +13.8% |
| Q4 2018 | $3,388,000 | +20.3% | 87,112 | +76.3% | 0.19% | +61.5% |
| Q3 2018 | $2,816,000 | -32.8% | 49,402 | -5.9% | 0.12% | -26.4% |
| Q2 2018 | $4,192,000 | +136.4% | 52,500 | +59.1% | 0.16% | +245.7% |
| Q2 2015 | $1,773,000 | +103.3% | 32,989 | +81.2% | 0.05% | +109.1% |
| Q1 2015 | $872,000 | – | 18,203 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |